Chemotherapy News and Research

Latest Chemotherapy News and Research

Functional genomics provide improved drug discovery

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins.

20 Apr 2004

Myriad Genetics advances drug for chemotherapy-induced nausea

Myriad Genetics, Inc. today released new data on MPC-4505, its Neurokinin-1 (NK1) receptor antagonist, a drug candidate for chemotherapy-induced nausea and vomiting (emesis). MPC-4505 is a potent, orally bioavailable, CNS-penetrating, highly selective NK1 antagonist.

20 Apr 2004

Bladder cancer is the fourth most common cancer in men and the eighth most common in women

Bladder cancer is the fourth most common cancer in men and the eighth most common in women, according to the National Cancer Institute (NCI). It is expected to be diagnosed in 38,000 men and 15,000 women in the United States in 2003. Treatment is most successful when the disease is caught early.

18 Apr 2004

How to beat throat cancer

Rochesterian Jim Toole is looking forward to a warm summer filled with hearty picnic barbecues after beating throat cancer.

16 Apr 2004

Tibetan yoga helps cancer and insomnia

The first study to look at the use of Tibetan yoga by cancer patients found the combination of movement and meditation led to a significant sleep benefit, say researchers at The University of Texas M. D. Anderson Cancer Center.

16 Apr 2004

Green tea helps kill cells of the most common leukemia

Mayo Clinic researchers have discovered that a component in green tea helps kill cells of the most common leukemia in the United States.

12 Apr 2004

Latest developments in prostate cancer research

New research on genes linked to hereditary prostate cancer helps scientists better understand how prostate cancer grows. Tests to find abnormal prostate cancer genes could also help tell which men are at high risk. They could then be tested more often. Further research could provide answers about the chemical changes that lead to prostate cancer. Then, perhaps, we could design drugs to reverse those changes.

12 Apr 2004

Molecular analyses of leukemia patients suggest strategies for better treatments

The cure rate for pediatric acute lymphoblastic leukemia (ALL) might continue to rise with improved use of conventional therapies. But even more effective and less toxic therapies based on genetic and pharmacogenetic studies might one day push the success rate close to 100 percent, according to an article published by investigators at St. Jude Children’s Research Hospital in the April 8 issue of the New England Journal of Medicine.

7 Apr 2004

Natural compound in snake venom for treatment of malignant tumours

Researchers at the University of South Australia have made a major discovery using a natural compound in snake venom that shows very promising anti-cancer effects. The compound works by activating the destruction of cells which make up the blood vessels that supply nutrients to tumours, according to Associate Professor Tony Woods from UniSA’s School of Pharmaceutical, Molecular and Biomedical Sciences.

30 Mar 2004

Zebrafish show effects of ionizing and UV radiation differ during embryo development

Adam Dicker, M.D., Ph.D., associate professor of radiation oncology at Jefferson Medical College of Thomas Jefferson University and Jefferson’s Kimmel Cancer Center in Philadelphia, Mary Frances McAleer, M.D., Ph.D., a resident in the Department of Radiation Oncology at Jefferson Medical College and their co-workers compared the effects on zebrafish embryos of two types of radiation – ionizing radiation, which is the kind given to patients for cancer treatment, and ultraviolet (UV) radiation, which comes naturally from the sun.

30 Mar 2004

Newly diagnosed non-Hodgkin’s lymphoma linked to monkey virus DNA

Examination of tumors in patients with newly diagnosed non-Hodgkin’s lymphoma found that half of them show evidence of a monkey virus DNA that may have originated from contaminated polio vaccines.

30 Mar 2004

New research to predict patient response to cancer chemotherapies

Timothy J. Yeatman, M.D., Moffitt's Associate Center Director for Clinical Investigations at the H. Lee Moffitt Cancer Center & Research Institute, and the Sarasota-based DNAPrintTM genomics, Inc., have formed a joint research program to develop and implement new clinical tests for predicting patient response to cancer chemotherapies.

29 Mar 2004

Data on pre-clinical activity of satraplatin in prostate cancer to be released

Spectrum Pharmaceuticals, Inc has announced that new data on pre-clinical activity of satraplatin in prostate cancer cell lines are being presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.

29 Mar 2004

p53 protein peptide stops cancer in its tracks

Researchers have dreamed of thwarting cancer by using proteins that halt cell growth and kill the tumor. In theory, the approach should work. In practice, however, scientists have not had an easy time of getting tumor suppressor proteins into cells where they can block growth effectively.

26 Mar 2004

Oral chemotherapy agent Orathecin™ (rubitecan) capsules accepted by FDA for filing

SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules’ New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.

26 Mar 2004

DNA repair enzymes to fight cancer

The body has a set of DNA repair enzymes that clean up damage to the genome, to reduce potential problems. Many commonly used cancer chemotherapies work by alkylating DNA. However, the DNA repair enzymes are just as capable of repairing this alkylation as if it were damage from any other source, and so they act to overcome the effects of the therapy, reducing its effectiveness.

22 Mar 2004

Chemotherapy offers new hope for pancreatic cancer patients

Chemotherapy after surgery more than doubles survival rates for pancreatic cancer according to new research published today (18 March 2004) in the New England Journal of Medicine. Scientists from the University of Birmingham and the University of Liverpool have carried out a Europe wide study of more than 280 patients over 10 years.

22 Mar 2004

Treatment for ovarian cancer by gene targeting

Targeting and inactivating a key gene could be a subtle and effective treatment for certain types of ovarian cancer, Scottish researchers suggest in a study published in Clinical Cancer Research.

22 Mar 2004

New Drug Offers Hope For Advanced Colorectal Cancer

Patients with advanced colorectal cancer have new hope for a longer life. The Food and Drug Administration recently approved the drug Avastin to be used in combination with chemotherapy. Doctors are calling it a big breakthrough.

22 Mar 2004